About 5.3 million Medicare Part D beneficiaries who rely on 15 high-cost drugs for cancer and chronic disease are set to pay less starting in 2027, after the federal government locked in a second round of price negotiations projected to save roughly $12 billion a year. The drugs collectively accounted for about $42.5 billion in gross covered prescription costs in 2024, representing approximately 14 percent of all Part D spending. Negotiations between CMS and drugmakers are running through 2025, with maximum fair prices taking effect two years from now.
Why the $12 billion projection faces a utilization test
The savings estimate rests on a comparison between current list prices and the negotiated maximum fair prices CMS will enforce beginning in 2027. But price is only half the equation. If prescribing volume for these 15 drugs grows faster than historical Part D trends, total spending could exceed or fall short of the projection by a wide margin. CMS selected the drugs partly because they already serve millions of patients; any shift in clinical guidelines, new competitor approvals, or expanded indications could push utilization higher. A reasonable reading of the evidence suggests the $12 billion figure could deviate by 15 percent or more within two years of implementation if demand moves meaningfully in either direction. The Brookings analysis arrived at a comparable gross savings estimate of approximately $12.5 billion using public data, but its analysts flagged methodological limits tied to the gap between observable list prices and true net prices after manufacturer rebates.
That gap matters for beneficiaries at the pharmacy counter. Negotiated maximum fair prices replace the list price for cost-sharing calculations, so patients filling these prescriptions should see lower copays regardless of what happens to rebate flows behind the scenes. For the federal budget, though, the net savings depend on how much manufacturers were already discounting through rebates that never showed up in the sticker price. If prior rebates were deep, the government’s net savings from negotiation could be smaller than the gross list-price cuts suggest, even as individual patients still benefit from lower out-of-pocket costs.
How CMS built the second negotiation round
CMS published the list of 15 Part D drugs selected for the second negotiation cycle, known as Initial Price Applicability Year 2027, in January 2025, according to a Government Accountability Office report reviewing early implementation of the Inflation Reduction Act’s drug pricing provisions. The agency had issued final guidance governing the process on October 2, 2024, with a formal effective date of December 9, 2024.
Drugmakers faced a hard deadline. Manufacturers of the selected drugs were required to decide whether to participate by February 28, 2025, according to CMS guidance. Opting out carries steep penalties under the Inflation Reduction Act, including an escalating excise tax on U.S. sales, which effectively made participation the only viable path for every company on the list. CMS has emphasized that the negotiated prices will apply across all Part D plans, limiting room for selective avoidance or plan-level carve-outs.
The 15 drugs treat conditions ranging from cancer to chronic disease and reached about 5.3 million enrollees in 2023, according to a CMS press release describing the expected impact on seniors and people with disabilities. The agency noted that these products accounted for a disproportionate share of Part D spending, which made them prime candidates for the second negotiation cycle under the Inflation Reduction Act’s criteria.
Which drugs are affected
The second negotiation round targets single-source brand-name drugs with no generic or biosimilar competition that have been on the market for years and rank among the highest-spend products in Medicare Part D. According to HHS announcements, the selected therapies span oncology, cardiovascular disease, autoimmune disorders, and other chronic conditions that often require long-term treatment. By focusing on drugs with sustained high spending and broad use, CMS aimed to maximize both fiscal savings and reductions in patient cost-sharing.
Detailed information on each product, including dosage forms, baseline prices, and the negotiated maximum fair prices that will apply in 2027, is available through the agency’s negotiation program listings. Those materials also outline how CMS calculated the discounts, taking into account factors such as clinical benefit, unmet medical need, and research and development costs, alongside statutory ceilings that cap the size of the price cut for each drug.
What beneficiaries and plans should expect next
Between now and 2027, the negotiated prices will move from preliminary figures into binding rates that Part D plans must honor. Plan sponsors will need to adjust formularies, preferred tiers, and pharmacy reimbursement structures to reflect the lower prices, while still complying with coverage requirements for the negotiated drugs. Beneficiaries are unlikely to see changes in which drugs are covered as a direct result of negotiation, but they should see lower coinsurance or copays once the maximum fair prices are in place.
For policymakers, the second negotiation cycle offers an early test of whether the Inflation Reduction Act’s approach can bend the Part D cost curve without disrupting access. If utilization remains stable and manufacturers continue to supply the drugs without interruption, the roughly $12 billion in projected annual savings could become a durable feature of the Medicare program. If, however, prescribing patterns shift sharply or new competitors enter the market and undercut negotiated prices, both the fiscal impact and the precedent for future negotiation rounds could look very different.
Free tool for readers: You check your blood pressure — when did you last check your retirement? You can get your free Retirement Safety Score in about five minutes, with no sign-up to see it.
